Mesial temporal sclerosis (MTS) is a common finding in patients with intractable temporal lobe epilepsy (TLE). In this report, we retrospectively reviewed the neuroimaging results of four children who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), and who developed recurrent, partial, intractable seizures following a first event caused by cyclosporine-A (CSA) neurotoxicity. Neuroradiologic findings of MTS were demonstrated in all these patients. We suggest that MTS may be a consequence of CSA neurotoxicity, which induces repeated seizures, associated with other predisposing conditions, as well as being a consequence of the underlying disease and its treatment, and of severe graft-versus-host disease (GvHD). Bone Marrow Transplantation (2003) 31, 919-922.
Summary:
Mesial temporal sclerosis (MTS) is a common finding in patients with intractable temporal lobe epilepsy (TLE). In this report, we retrospectively reviewed the neuroimaging results of four children who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), and who developed recurrent, partial, intractable seizures following a first event caused by cyclosporine-A (CSA) neurotoxicity. Neuroradiologic findings of MTS were demonstrated in all these patients. We suggest that MTS may be a consequence of CSA neurotoxicity, which induces repeated seizures, associated with other predisposing conditions, as well as being a consequence of the underlying disease and its treatment, and of severe graft-versus-host disease (GvHD). Bone Marrow Transplantation (2003) 31, 919-922. doi:10.1038/sj.bmt.1704023 Keywords: cyclosporine neurotoxicity; intractable temporal epilepsy; mesial temporal sclerosis Acute encephalopathy has been recognized as a complication of cyclosporine-A (CSA) therapy that is used to prevent and treat graft-versus-host disease (GvHD) in allogeneic recipients. Neurological CSA side effects are usually reversible after discontinuing CSA, and frequently occur in conjunction with high blood pressure. The clinical picture of CSA neurotoxicity may include visual disturbances, headache, seizures, changes in mental state, and motor or sensory disorders. Magnetic resonance imaging (MRI) obtained in patients with acute CSA neurotoxicity usually shows posterior reversible encephalopathy syndrome (PRES), gray and white matter focal changes, vascular injury in watershed areas, or central pontine myelinolysis. [1] [2] [3] Nevertheless, few cases with persistent epilepsy after CSA discontinuation have been reported. 2 We reviewed the clinical records and neuroimaging results of four pediatric hematopoietic stem cell transplantation (HSCT) recipients treated at the G Gaslini Children's Research Institute, who developed recurrent partial intractable seizures after having experienced a previous episode of CSA neurotoxicity. The characteristics of these patients are listed in Table 1 . In all cases, MRI revealed hippocampal abnormalities consistent with mesial temporal sclerosis (MTS), which is the most common pathological lesion observed in patients with temporal lobe epilepsy. The disabling complex seizures observed in patients with MTS are often drug resistant and may improve after surgical resection of the epileptic focus. 4 
Case 1
A 6-year-old boy suffering from acute lymphoblastic leukemia (ALL) underwent related donor HSCT in second complete remission. His frontline treatment included standard chemotherapy and prophylactic intrathecal MTX/Ara-C (total: 24 doses). Conditioning included TBI, CY, and VCR. GvHD prophylaxis was with CSA, 1 mg/kg/day i.v. The post-transplant period (day +50) was complicated by cutaneous (grade 1) and hepatic (grade 3) acute GvHD, which were treated with high-dose prednisolone. On day 77 after HSCT, he developed generalized seizures associated with elevated blood pressure. The CSA level was 377 ng/ml (therapeutic range between 100 and 250 ng/ml). The neurologic clinical picture was characterized by visual disturbances followed by generalized seizures; the electroencephalogram (EEG) showed slow central-posterior parossistic anomalies, and brain computed tomography (CT) scan showed a diffuse atrophic pattern associated with slight ventricular asymmetry with minimal enlargement of the right temporal horn. These features as well as a routine blood and cerebrospinal fluid (CFS) examination ruled out a metabolic or infectious pathogenesis of the episode and were strongly suggestive of CSA neurotoxicity. CSA was discontinued for 2 days, then reintroduced at 10% of the previous dose with subsequent increases until therapeutic levels. After 1 month, while on immunosuppresive therapy (CSA, steroids, extracorporeal photopheresis -ECP) for persistent severe hepatic GvHD, the child developed partial complex seizures with left laterality. These complex episodes recurred monthly despite anticonvulsant therapy; EEGs showed bilateral central-occipital slow abnormalities with paroxysmal activity in the right central-temporal region and CT scans revealed no significant abnormality. At 11 months after HSCT, MRI demonstrated right MTS (Figure 1 ). At 42 months after transplant, a liver biopsy showed the absence of active liver GvHD, and all immunosuppressive therapies were discontinued. Despite this, intractable complex partial seizures continue to occur 7 years after HSCT. Surgical excision of the epileptic focus has been proposed to the patient, and is currently being evaluated.
Case 2
Hemophagocytic lymphohistiocytosis (HLH) was diagnosed in a 7-month-old male. Central nervous system (CNS) involvement was documented by 500/mm 3 histiocytes in the CSF; brain CT scan and neurological examination were negative. The clinical picture at onset was characterized by multiple organ failure with cardiac arrest. After resuscitation, the neurological status of the patient was normal and chemotherapy, inclusive of CSA and four doses of intrathecal MTX, was started according to the HLH-94 protocol proposed by the Histiocyte Society. Treatment ended following an unrelated donor HSCT performed at the age of 2.9 years in the presence of active cutaneous/liver disease and absence of CNS involvement according to MRI imaging and CSF examination. He received BU, CY, VP-16 for pretransplant conditioning, and CSA (3 mg/kg/day i.v.), rabbit antithymocyte globulin (ATG), and short course MTX for GvHD prophylaxis. During the first 100 days after HSCT, he had acute cutaneous GvHD (grade 3) which was responsive to highdose of steroids. After 3 months, the child developed CSA neurotoxicity characterized by high blood pressure, visual disturbances, and generalized seizures. CSA blood levels were within the therapeutic ranges. CT scan showed diffuse brain atrophy, especially involving the left temporal lobe. After 9 months, the patient showed a complex neurologic picture characterized by intractable, complex, partial seizures occurring several times every month, and by a progressive mental disorder with cognitive impairment in the framework of extensive cutaneous chronic GvHD. Relapse of CNS-HLH was excluded on the basis of the full donor origin of CSF cells by means of short tandem repeat (STR) analysis. Viral pathogens (HHV6, EBV, CMV, Human papovavirus JC) were also ruled out by negative PCR on CSF. This picture, associated with an angiitis-like MRI pattern, 5, 6 suggested an immunomediated neurological complication that led to treatment with CSA, steroids, and ECP. The EEG showed slow bilateral occipital and paroxysmal activity prevailing on the left side. An MRI performed 14 months after HSCT, when the child was on combined immunosuppression with CSA and steroids, displayed an increased signal on T2-weighted images and flattening of the hippocampal head consistent with left MTS. The temporal horn was clearly enlarged. CSA was discontinued 4.3 years after HSCT but seizures refractory to anticonvulsant therapy still persist 6 years after transplant. 
Case 3
A 4-year-old male with osteopetrosis received related donor HSCT after conditioning with BU, CY, and Thiotepa, while GvHD prophylaxis included CSA (1 mg/kg/day i.v). Febrile seizures and mild psychomotor retardation were reported before transplant. MRI performed before HSCT was negative except for brain atrophy attributable to the underlying disease. After transplant he developed acute cutaneous GvHD (grade 3) that was treated with high doses of prednisolone. On day 53 after HSCT the patient showed cortical blindness followed by generalized seizures with CSA levels far above the accepted therapeutic range (2410 ng/ml).
A CT scan performed shortly after the first event showed only a slight enlargement of the right temporal horn that progressively dilated over the ensuing time period. Subsequently, the child developed extensive, chronic cutaneous GvHD treated with psoralen in combination with UVA (PUVA) and immunosuppressive therapy. Five months after the first episode of CSA neurotoxicity the patient developed a partial motor seizure. CSA was definitively discontinued 2 months later (9 months after HSCT) and other immunosuppressive agents were substituted. MRI was performed 1.9 years after HSCT and led to the diagnosis of right MTS. Imaging revealed, increased signals on the hippocampal head, and focal enlargement of the temporal horn associated with slight ipsilateral temporal neocortical atrophy. To date, 7 and 9 years after immunosuppression discontinuation and HSCT, respectively, complex partial seizures continue to occur. MRI is stable and repeated EEGs show mild, slow abnormalities.
Case 4
A 20-month-old boy suffering from HLH without CNS involvement received CSA therapy according to the HLH-94 protocol and underwent unrelated-donor HSCT at the age of 3 years. The preparative regimen and GvHD prophylaxis were the same as in Case 1, with the exception of CAMPATH 1G instead of ATG. Only slight brain atrophy with minimal enlargement of the right temporal horn were evident on the CT scan performed before transplant. The early post-transplant course was complicated by grade 1 gastrointestinal GvHD and mild thrombotic microangiopathy which led to CSA dose reduction. After 2 months the child had a first episode of neurologic CSA toxicity characterized by grade 2 coma, followed by generalized seizures and hypertension. CSA blood levels were 375 ng/ml. At that time no changes on CT were observed compared with the previous examination. CSF examination was inconclusive. The boy quickly recovered after CSA discontinuation, which was reintroduced 10 days after the event at a reduced dose. After 2 weeks, partial motor seizures occurred and similar episodes with secondary generalization repeated several times in the following months; during this period the child was receiving therapeutic doses of CSA. EEG showed diffuse epileptiform discharges with focal paroxysmal activity in the central occipital region. At 11 months after HSCT, MRI demonstrated right MTS which was characterized by abnormalities in the mesial cortex and by temporal horn enlargement. CSA was discontinued 21 months after transplant but intractable recurrent partial seizures with right laterality persist 5 years after HSCT.
Discussion
MTS is considered a highly epileptogenic lesion and includes changes in the hippocampus, amygdala, and adjacent entorhinal cortex. Prolonged febrile seizures occurring between 3 and 7 years of age are the most frequently reported risk factors for MTS. 4 A high frequency of MTS is also reported in patients with brain developmental malformations (ie temporal cortical dysplasia). 4 Anoxia, head injuries, or viral encephalitis are other possible risk factors. 7 These injuries produce a disruption of the physiological balance between excitatory and inhibitory mechanisms followed by the release of excitatory amino acids, primarily glutamate. 8 The result is a neuronal loss in specific vulnerable areas of the hippocampus. Bilateral MTS is more commonly observed after early perinatal injuries, while unilateral lesions are more often associated with late vascular damage. 4 Only brain MRI using T2-weighted or FLAIR and other optimized sequences allows for appropriate diagnosis of MTS by showing an increased signal of the hippocampus and an enlargement of the ipsilateral temporal horn, with or without associated temporal neocortical atrophy. 4, 9 CT scan usually only allows recognition of nonspecific signs of temporal atrophy. 10 MTS has never been described after transplant except in the context of human herpesvirus 6 encephalitis. 11 In our report we describe four boys with a median age of 43 months at the time of allogeneic HSCT, who developed intractable partial seizures secondary to unilateral MTS diagnosed by MRI. All the patients experienced an episode of CSA neurotoxicity within the first three months after HSCT and suffered from both acute and chronic GvHD requiring multidrug treatment. At the time of their first CSA-related neurotoxic event, neither CSF examination nor clinical-instrumental findings showed any viral infections and/or brain malformations. The MTS was documented after a median of 16 months from HSCT (range 11-21 months). At that time all children but one (case 3) were receiving therapy with CSA alone or in association with other immunosuppressive drugs.
CSA neurotoxicity is considered to be the expression of direct neuronal synaptic hyperexcitability, 12 or of indirect damage because of brain vasculopathy through the release of vasoconstrictors (endothelin or thromboxane) which cause vasospasm. 13 The pathological result is watershed hypoperfusion with consequent neuronal necrosis. We suggest that the MTS that was observed in our patients may have been the result of the association between previous acute CSA neurotoxicity that cause repeated seizures and the underlying conditions predisposing to selective hippocampal neuronal loss. The clinical history of our cases showed various other factors that might play a role in the development of MTS, ie, CSA administration included in first line therapy given to the two patients with HLH, CNS involvement by HLH associated with a previous anoxic injury in the child with temporary cardiac arrest, previous febrile seizures in the patient with osteopetrosis. The interaction between these conditions, ie, neurotoxic treatment given in first line therapy and in the conditioning regimens, and severe acute or chronic GvHD and CSA-related neurotoxicity, which were observed in all children, may have induced irreversible vascular damage leading to hippocampal shrinkage. This hypothesis is sustained by the unilaterality of the MTS lesions and by the age of the children (between 3 and 6 years) when the possible endothelial damage occurred. 14 After the diagnosis of MTS these children had a MRI follow-up once a year. The MRI findings showed stable MTS despite intractable epilepsy. Early recognition of MTS is therefore of great importance since surgical treatment in selected cases might be indicated. 4, 15 
